According to our (Global Info Research) latest study, the global Taletrectinib Adipate market size was valued at US$ 46.30 million in 2025 and is forecast to a readjusted size of US$ 436 million by 2032 with a CAGR of 25.2% during review period.
Taletrectinib Adipate is an oral, highly selective small‑molecule tyrosine kinase inhibitor and a new generation of antineoplastic agent targeting ROS1 and NTRK fusion genes. It exerts potent antitumor activity by selectively inhibiting ROS1 and NTRK kinase activities, blocking downstream signaling pathways involved in tumor cell proliferation, differentiation and metastasis. It demonstrates significant inhibitory activity against crizotinib‑resistant mutations such as ROS1 G2032R. It is mainly indicated for the treatment of ROS1‑positive advanced or metastatic non‑small cell lung cancer and NTRK fusion‑positive solid tumors, characterized by strong antitumor activity, excellent central nervous system penetration and broad coverage of resistant mutationsIn 2025, global taletrectinib adipate (己二酸他雷替尼,brand name Ibtrozi) production reached approximately 120,000–150,000 bottles
Taletrectinib adipate demonstrates significant market competitiveness in the global treatment of ROS1 and NTRK fusion-positive tumors owing to its excellent target selectivity, potent intracranial antitumor activity, and favorable control over drug-resistant mutations. With the popularization of precision medicine and genetic testing, the clinical demand for such targeted drugs continues to rise. By virtue of its superior efficacy and safety compared with first-generation products, taletrectinib adipate has gradually become an important option for the treatment of advanced non-small cell lung cancer and solid tumors. Driven by policy support at home and abroad, the advancement of medical insurance access, and global commercialization layout, its market coverage has been continuously expanded and patient accessibility steadily improved. The overall market shows a steady growth trend, with broad application prospects and promising market potential in both first-line and post-resistance treatment settings.
This report is a detailed and comprehensive analysis for global Taletrectinib Adipate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Taletrectinib Adipate market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Taletrectinib Adipate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Taletrectinib Adipate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Taletrectinib Adipate market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Taletrectinib Adipate
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Taletrectinib Adipate market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AnHeart Therapeutics, Innovent Biologics, Asymchem Life Sciences Tianjin) C, Daiichi Sankyo, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Taletrectinib Adipate market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
33 capsules / bottle
30 capsules / bottle
Market segment by Indicated Population
ROS1 Fusion Gene-Positive Adult Patients with Advanced or Metastatic Non-Small Cell Lung Cancer**
NTRK Fusion Gene-Positive Patients with Advanced Solid Tumors**
Market segment by Sales Channels
Hospitals
Retail
Online
Market segment by Production Technology
Original
Generic
Market segment by Application
Ros1 Fusion-Positive Locally Advanced
Metastatic Non-Small Cell Lung Cancer (NSCLC)
Others
Major players covered
AnHeart Therapeutics
Innovent Biologics
Asymchem Life Sciences Tianjin) C
Daiichi Sankyo
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Taletrectinib Adipate product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Taletrectinib Adipate, with price, sales quantity, revenue, and global market share of Taletrectinib Adipate from 2021 to 2026.
Chapter 3, the Taletrectinib Adipate competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Taletrectinib Adipate breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Taletrectinib Adipate market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Taletrectinib Adipate.
Chapter 14 and 15, to describe Taletrectinib Adipate sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Taletrectinib Adipate. Industry analysis & Market Report on Taletrectinib Adipate is a syndicated market report, published as Global Taletrectinib Adipate Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Taletrectinib Adipate market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.